Intake of Individual Fatty Acids and Risk of Prostate Cancer in the European Prospective Investigation into Cancer and Nutrition

Aurora Perez-Cornago¹, Inge Huybrechts², Paul N. Appleby¹, Julie A. Schmidt¹, Francesca L. Crowe³, Kim Overvad⁴, Anne Tjønneland⁵, Tilman Kühn⁶, Verena Katzeke⁶, Antonia Trichopoulou⁷, Anna Karakatsani⁷,⁸, Eleni Peppa⁷, Sara Grioni⁹, Domenico Palli¹⁰, Carlotta Sacerdote¹¹, Rosario Tumino¹², H. Bas Bueno-de-Mesquita¹³,¹⁴,¹⁵,¹⁶, Nerea Larrañaga¹⁷,¹⁸, María-Jose Sánchez¹⁸,¹⁹, J. Ramón Quirós²⁰, Eva Ardanaz¹⁸,¹¹,²², María-Dolores Chirlaque¹⁸,²³,²⁴, Antonio Agudo²⁵, Anders Bjartell²⁶,²⁷, Peter Wallström²⁸,²⁹, Veronique Chajes³⁰, Konstantinos K. Tsilidis³¹,³², Dagfinn Aune³²,³³,³⁴, Elio Riboli³², Ruth C. Travis¹, Timothy J. Key¹

¹ Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom
² Dietary Exposure Assessment Group, International Agency for Research on Cancer, Lyon, France
³ Institute of Applied Health Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom
⁴ Department of Public Health, Section for Epidemiology, Aarhus University, Aarhus C, Denmark
⁵ Danish Cancer Society Research Center, Copenhagen, Denmark
⁶ Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany
7 Hellenic Health Foundation, Athens, Greece
8 Pulmonary Medicine Department, School of Medicine, National and Kapodistrian University of Athens, “ATTIKON” University Hospital, Haidari, Greece
9 Epidemiology and Prevention Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy
10 Cancer Risk Factors and Life-Style Epidemiology Unit, Institute for Cancer Research, Prevention and Clinical Network - ISPRO, Florence, Italy
11 Unit of Cancer Epidemiology, Città della Salute e della Scienza University-Hospital and Center for Cancer Prevention (CPO), Turin, Italy
12 Cancer Registry and Histopathology Department, "Civic - M.P. Arezzo" Hospital, ASP Ragusa, Italy
13 Former senior scientist, Department for Determinants of Chronic Diseases (DCD), National Institute for Public Health and the Environment (RIVM), PO Box 1, 3720 BA Bilthoven, The Netherlands
14 Former associate professor, Department of Gastroenterology and Hepatology, University Medical Centre, Utrecht, The Netherlands
15 Former Visiting professor, Department of Epidemiology and Biostatistics, The School of Public Health, Imperial College London, St Mary’s Campus, Norfolk Place, London, W2 1PG London, United Kingdom
16 Former Academic Icon / visiting professor, Dept. of Social & Preventive Medicine, Faculty of Medicine, University of Malaya, Pantai Valley, 50603, Kuala Lumpur, Malaysia
Public Health Division of Gipuzkoa-BIODONOSTIA, Basque Regional Health Department, Spain

CIBER of Epidemiology and Public Health, Madrid, Spain

Escuela Andaluza de Salud Pública. Instituto de Investigación Biosanitaria ibs.GRANADA. Hospitales Universitarios de Granada/Universidad de Granada, Granada, Spain

Public Health Directorate, Asturias, Spain

Navarra Public Health Institute, Pamplona, Spain

IdiSNA, Navarra Institute for Health Research, Pamplona, Spain

Department of Epidemiology, Regional Health Council, IMIB-Arrixaca, Murcia, Spain

Department of Health and Social Sciences, Universidad de Murcia, Murcia, Spain

Unit of Nutrition and Cancer, Cancer Epidemiology Research Program, Catalan Institute of Oncology-IDIBELL. L’Hospitalet de Llobregat, Barcelona, Spain

Department of Translational Medicine, Medical Faculty, Lund University, Malmö, Sweden

Department of Urology, Skåne University Hospital, Malmö, Sweden

Nutrition Epidemiology Research Group, Department of Clinical Sciences, Lund University, Malmö, Sweden

Clinical Research Centre, Malmö University Hospital, SE-205 02 Malmö, Sweden

Nutrition and Metabolism, International Agency for Research on Cancer, Lyon, France

Department of Hygiene and Epidemiology, University of Ioannina School of Medicine, Greece
32 Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, United Kingdom

33 Department of Nutrition, Bjørknes University College, Oslo, Norway

34 Department of Endocrinology, Morbid Obesity and Preventive Medicine, Oslo University Hospital, Oslo, Norway

**Short title:** Intake of individual fatty acids and prostate cancer risk

**Correspondence to:** Dr. Aurora Perez-Cornago, Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom, OX3 7LF. TEL: +44 (0)1865 289600; FAX: +44 (0)1865 289610; EMAIL: aurora.perez-cornago@ndph.ox.ac.uk

**Keywords:** prostate cancer, individual fatty acids, tumor subtypes, prospective.

**Abbreviations:** Body Mass Index (BMI), confidence intervals (CIs), European Prospective Investigation into Cancer and Nutrition (EPIC), food-frequency questionnaire (FFQ), insulin-like growth factor-I (IGF-I), International Statistical Classification of Diseases, Injuries and Causes of Death (ICD), hazard ratios (HRs), monounsaturated fatty acids (MUFAs), National Nutrient Database for Standard Reference of the United States (NNDSR = USDA), prostatic intraepithelial neoplasia (PIN), prostate-specific antigen (PSA), polyunsaturated fatty acids (PUFAs), saturated fatty acids (SFAs), standard deviations (SDs), tumor-node-metastasis (TNM), United Kingdom (UK), World Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR).

**Appropriate Article category:** Cancer Epidemiology
**Novelty and Impact**: The role of individual dietary fatty acids in prostate cancer risk is uncertain. We examined the prospective association of individual dietary fatty acids with the incidence of prostate cancer. Our findings indicated that a higher intake of butyric acid was associated with a higher risk of advanced stage prostate cancer, whereas intakes of eicosenoic and eicosapentaenoic acids were positively associated with fatal prostate cancer risk. We found no associations with overall prostate cancer.

**Conflicts of interest**: No authors report conflicts of interest.

**Financial support**: These analyses were supported by Cancer Research UK (C8221/A19170). The coordination of EPIC is financially supported by the European Commission (DG-SANCO) and the International Agency for Research on Cancer. The national cohorts are supported by Danish Cancer Society (Denmark); German Cancer Aid, German Cancer Research Center (DKFZ), Federal Ministry of Education and Research (BMBF), Deutsche Krebshilfe, Deutsches Krebsforschungszentrum and Federal Ministry of Education and Research (Germany); the Hellenic Health Foundation (Greece); Associazione Italiana per la Ricerca sul Cancro-AIRC-Italy and National Research Council (Italy); Dutch Ministry of Public Health, Welfare and Sports (VWS), Netherlands Cancer Registry (NKR), LK Research Funds, Dutch Prevention Funds, Dutch ZON (Zorg Onderzoek Nederland), World Cancer Research Fund (WCRF), Statistics Netherlands (The Netherlands); Health Research Fund (FIS) PI13/00061 (EPIC-Granada) and, PI13/01162 (EPIC-Murcia), Regional Governments of Andalucia, Asturias, Basque Country, Murcia and Navarra, ISCIII Health Research Funds RD12/0036/0018 (cofounded by FEDER funds/European Regional Development Fund ERDF) (Spain); Swedish Cancer Society, Swedish Research Council and
County Councils of Skåne and Västerbotten (Sweden); Cancer Research UK (14136 to EPIC-Norfolk; C570/A16491 for EPIC-Oxford), Medical Research Council (1000143 to EPIC-Norfolk, MR/M012190/1 to EPIC-Oxford) (UK).

For information on how to submit an application for gaining access to EPIC data and/or biospecimens, please follow the instructions at [http://epic.iarc.fr/access/index.php](http://epic.iarc.fr/access/index.php)
Abstract

The associations of individual dietary fatty acids with prostate cancer risk have not been examined comprehensively. We examined the prospective association of individual dietary fatty acids with prostate cancer risk overall, by tumor subtypes, and prostate cancer death. 142,239 men from the European Prospective Investigation into Cancer and Nutrition who were free from cancer at recruitment were included. Dietary intakes of individual fatty acids were estimated using center-specific validated dietary questionnaires at baseline and calibrated with 24-hour recalls. Multivariable Cox regression models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs). After an average follow-up of 13.9 years, 7,036 prostate cancer cases and 936 prostate cancer deaths were ascertained. Intakes of individual fatty acids were not related to overall prostate cancer risk. There was evidence of heterogeneity in the association of some short chain saturated fatty acids with prostate cancer risk by tumor stage ($P_{\text{heterogeneity}}<0.015$), with a positive association with risk of advanced stage disease for butyric acid (4:0; $HR_{1SD}=1.08$; 95%CI=1.01-1.15; $P$-trend=0.026). There were no associations with fatal prostate cancer, with the exception of a slightly higher risk for those who consumed more eicosenoic acid (22:1n-9c; $HR_{1SD}=1.05$; 1.00-1.11; $P$-trend=0.048) and eicosapentaenoic acid (20:5n-3c; $HR_{1SD}=1.07$; 1.00-1.14; $P$-trend=0.045). There was no evidence that dietary intakes of individual fatty acids were associated with overall prostate cancer risk. However, a higher intake of butyric acid might be associated with a higher risk of advanced, whereas intakes of eicosenoic and eicosapentaenoic acids might be positively associated with fatal prostate cancer risk.
Introduction

Prostate cancer is the most frequently diagnosed cancer in men in Europe \(^1\), but the well-established risk factors age, ethnicity, genetic factors and family history of the disease are not modifiable \(^2\,^3\). There is also evidence that circulating insulin-like growth factor-I (IGF-I) is related to higher overall prostate cancer risk \(^4\), and obesity has been associated with a higher risk of aggressive disease \(^5\). Moreover, the wide international variation in prostate cancer incidence and the changing rates observed in migrant studies suggest that environmental and lifestyle factors, such as dietary factors, are possible risk factors for the disease \(^6\). However, some of this international variation is due to differences between countries in prostate-specific antigen (PSA) testing, which has especially increased the diagnosis of nonaggressive tumors \(^1\); therefore to provide more clarity on prostate cancer etiology it is important that analytical studies characterize prostate cancer by stage, grade and fatality of the disease.

The possible role of total and specific types of dietary fats in relation to prostate cancer development and progression has attracted much interest \(^7\,^8\). The latest meta-analysis from the World Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR) stated that the evidence was limited and no conclusion could be reached on whether consumption of total fat, saturated fatty acids (SFAs), monounsaturated fatty acids (MUFAs), or polyunsaturated fatty acids (PUFAs) is associated with overall prostate cancer risk or with risk for ‘advanced/high grade’ prostate cancer \(^2\,^9\). However, this meta-analysis did not differentiate between stage and grade of the disease because of the small number of available studies with data on both these outcomes, and associations with prostate cancer death were not available. Moreover, recent studies have shown that individual fatty acids may confer
heterogeneous health effects\textsuperscript{10-12}, which might explain the current inconclusive results on the role of dietary fat on prostate cancer.

The aim of this study was to examine the association of intakes of individual dietary fatty acids with the risk of prostate cancer, and to examine whether any associations differ by tumor grade, stage, or for death from prostate cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC).

**Material and methods**

*Subjects and study design*

EPIC includes 153,457 men recruited between 1992 and 2000 from 19 centers, most aged 35-70 years, in 19 centers in eight European countries (Denmark, Germany, Greece, Italy, Netherlands, Spain, Sweden and United Kingdom (UK)) (more details in Supplementary Methods). The details of the study design used in the EPIC study have been described elsewhere \textsuperscript{13}. Men were not eligible for this analysis if they were diagnosed with cancer (except non-melanoma skin cancer) before recruitment (n = 3,972), if they had missing dates of prostate cancer diagnosis (n = 14) or follow-up (n = 1,433), or if they were aged <20 years at recruitment (n = 2). Men were also excluded if they had no non-dietary or dietary data, or if they had an extreme energy intake in relation to estimated requirement (top and bottom 1%, n = 5,766) \textsuperscript{14}. Complete data on diet and follow-up for prostate cancer were available for 142,239 men (Supplementary Figure 1).

*Assessment of dietary intake and other predictor variables*
At baseline, information was collected on lifestyle, health status, socio-demographic characteristics, anthropometry and medical history. Dietary intake during the year before enrolment was measured by country- or center-specific validated food frequency questionnaires (FFQs) or diet histories, as previously described. To correct for any systematic under- or overestimation of dietary intake across the participating centers, dietary intakes from the questionnaires were calibrated using a standardized, computer-based, 24-h dietary recall method in an 8% random sample of the whole EPIC cohort.

In order to estimate the intakes of individual fatty acids, the EPIC Nutrient Database (ENDB) was matched with the National Nutrient Database for Standard Reference of the United States (NNDSR; developed at the USDA). The fatty acid intakes reported in this manuscript were obtained through this extra USDA matching (more details in Supplementary Methods). Due to the very small amounts of some individual fatty acids, we only included those with a mean total intake of at least 0.05 grams/day in these analyses, with the exception of docosapentaenoic acid (22:5n-3c), which was included due to its previously suggested role in prostate cancer risk. Fatty acids were presented and analyzed as grams per 1000 kcal/day in order to control for confounding by total energy intake. Short chain fatty acids were strongly correlated with each other (Supplementary table 2A), probably because of their shared food sources; therefore, in addition to analyzing short chain SFAs individually, they were also combined together in groups as 4:0-10:0 and 12:0-14:0.

Ascertainment of prostate cancer

The main source of information on cancer incidence, tumor subtypes and vital status was population-based cancer and mortality registries. In Germany and Greece follow-up was
based on a combination of methods, including health insurance records, cancer and pathology registries, as well as active follow-up through participants or relatives; self-reported incident cancers were verified through medical records. Follow-up began at the date of recruitment and was censored at the date of last known contact, or at the date of diagnosis of cancer, death, emigration or the end of the follow-up period, whichever came first. Prostate cancer \((n = 7,036)\) was defined as code C61 in the 10th Revision of the International Statistical Classification of Diseases, Injuries and Causes of Death (ICD) 19.

Grade (based on Gleason sum) was classified as low-intermediate (Gleason sum of < 8, or grade coded as well, moderately, or poorly differentiated; \(n = 3,757)\) or high (Gleason sum of \(\geq 8,\) or grade coded as undifferentiated; \(n = 726)\) grade. Information on stage was based on tumor-node-metastasis (TNM) staging code. Localized stage included those confined within the prostate and with no metastases at diagnosis (TNM staging score of \(\leq T_2 \text{ and } N_0/N_x \text{ and } M_0,\) or stage coded in the recruitment center as localized; \(n = 2,641)\). Advanced cases included tumors that had spread beyond the prostate at diagnosis (\(T_3-T_4 \text{ and/or } N_1-N_3 \text{ and/or } M_1,\) and/or stage coded in the recruitment center as metastatic; \(n = 1,389)\). Fatal cases were those who died of prostate cancer \((n = 936)\).

**Statistical analysis**

Baseline characteristics of the study population were calculated across fifths of total SFAs, MUFAs and PUFAs intake in grams/1000 kcal and presented as means with standard deviations (SDs) for continuous variables or percentages for categorical variables. Pearson correlations between intakes of individual SFAs, MUFAs and PUFAs were calculated.
Each individual fatty acid was divided into fifths of intake in grams/1000 kcal/day based on the distribution in the EPIC cohort and also modeled as continuous variables per SD higher intake.

Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated using Cox proportional hazards models using attained age as the underlying time variable. The date of last follow-up ranged from January 2011 in Germany to October 2013 in Spain. All analyses were stratified by center and age (<50, 50-54.9, 55-59.9, 60-64.9, 65-69.9, and ≥70 years) at recruitment. To check for violation of the proportional hazards assumption we used time-varying covariates and Schoenfeld residuals, which did not indicate violation from the proportional hazards assumption. Tests for linear trend were performed using continuous values for dietary fatty acids, with increments based on one SD increase. All models were adjusted for educational level (no degree or equivalent, degree or equivalent, unknown), smoking status (never, former, current, unknown), marital status (married or cohabiting, not married or cohabiting, unknown), diabetes (no, yes, unknown), physical activity (inactive, moderately inactive, moderately active, active, unknown 20), height (<170, 170–174, 175–179, ≥180 cm, unknown), BMI (<22.5, 22.5–24.9, 25–29.9, ≥30 kg/m^2, unknown), and total energy intake (fifths). Participants with missing values were assigned an “unknown” category; <3% of values were missing for each covariate, with the exception of marital status, for which 30% of values were missing.

Tests for heterogeneity of trends for histologic grade (low-intermediate or high), tumor stage (localized or advanced), and time between blood collection and diagnosis (<5 years, ≥5 years)] were performed. For this, we fitted separate models for each subgroup assuming
independence of the HRs using a method analogous to competing risks, and compared the risk coefficients and standard errors in the subgroups of interest after excluding cases of unknown grade or stage.

All analyses were performed using Stata version 14.1 (Stata Corporation, College Station, TX, USA), all tests of significance were two-sided, and a P-value less than 0.05 was considered statistically significant. Conventional p-values are shown but the results were interpreted in the light of the number of tests performed.

Results

A total of 7,036 men were diagnosed with prostate cancer after an average follow-up time of 13.9 years. The median age at prostate cancer diagnosis was 68 years (range, 41-95 years).

Table 1 shows the characteristics of the study participants at baseline. Some baseline characteristics varied by fatty acids consumption. For example, men in the highest fifth of SFAs intake were more likely to have an education degree and have a higher total energy intake. Men in the highest fifths of MUFAs and PUFAs intake were more likely to be younger at recruitment and older at prostate cancer diagnosis.

Palmitic acid (16:0), oleic acid (18:1n-9c) and linoleic acid (18:2n-6c) were the largest contributors to total SFAs, MUFAs and PUFAs intake, respectively (Supplementary table 1). Butyric acid (4:0), caproic acid (6:0), caprylic acid (8:0) and capric acid (10:0) were strongly correlated with each other (correlation coefficients ranged from 0.840 to 0.972). There was also a strong correlation between palmitic acid (16:0) and stearic acid (18:0) (correlation coefficient 0.814, Supplementary Table 2A). Although individual MUFAs were
correlated, these correlations were not very strong (Supplementary Table 2B). The PUFAs eicosapentaenoic acid (20:5n-3c), docosapentaenoic acid (22:5n-3c) and docosahexaenoic acid (22:6n-3c) were also strongly correlated (correlation coefficients ranged from 0.872 to 0.968, Supplementary Table 2C).

The associations of intakes of individual SFAs, MUFAs and PUFAs with risk for overall prostate cancer, prostate cancer subdivided by grade and stage of disease, and for prostate cancer death, using both the observed and calibrated intakes, are shown in Tables 2 (Supplementary Table 3 for observed intakes), 3 (Supplementary Table 4 for observed intakes), and 4 (Supplementary Table 5 for observed intakes), respectively. Results for observed and calibrated intakes were similar in direction; therefore, from here on we will only report calibrated results.

Intakes of individual SFAs, MUFAs and PUFAs were not related to overall prostate cancer risk (Supplementary table 6 and Tables 2, 3 and 4). Removing BMI as a covariate in the model has no impact on any of the results. There was no evidence of heterogeneity in separate analyses by grade (Tables 2, 3 and 4). We found evidence of heterogeneity in the association of some SFAs [butyric acid (4:0), caproic acid (6:0), 4:0-10:0 combined and 12:0-14:0 combined] with prostate cancer risk by tumor stage (P_heterogeneity for all < 0.03; Table 2), with a positive association with risk of advanced stage disease for butyric acid (4:0; HR_{1SD in calibrated intake} = 1.08; 1.01-1.15; P-trend=0.026), and no significant associations with localized disease. There was also evidence of heterogeneity by tumor stage (P_heterogeneity = 0.021) in the association between arachidonic acid (20:4n-6c) with prostate cancer risk, with a higher
intake of this PUFA being weakly associated with a lower risk of advanced disease (HR_{1SD in calibrated intake} = 0.91, 0.82-1.01; P-trend=0.072; Table 4).

We observed no associations between intakes of individual dietary fatty acids and prostate cancer death, with the exception of a small increased risk for those with a higher intake of eicosenoic acid (22:1n-9c; HR_{1SD in calibrated intake} = 1.05; 95% CI 1.00-1.11; P-trend=0.048; Table 3) and eicosapentaenoic acid (20:5n-3c; HR_{1SD in calibrated intake} = 1.07; 95% CI 1.00-1.14; P-trend=0.045; Table 4).

Although there was some evidence of heterogeneity for the association of some long-chain SFAs with total prostate cancer risk when subdivided by time between recruitment and diagnosis (<5 years, ≥5 years; Supplementary Table 7), the associations at each of the follow-up times were not statistically significant. There was no evidence of heterogeneity for the rest of individual fatty acids by follow-up time.

Discussion

In this large prospective study, intakes of individual fatty acids were not associated with overall prostate cancer risk. However, a higher intake of butyric acid was positively associated with risk for advanced stage prostate cancer. There was also a small increased risk of fatal prostate cancer risk with higher intakes of eicosenoic acid and eicosapentaenoic acid.

The possible association between fat intake (total fat and specific fatty acids) with prostate cancer risk and/or progression has generated considerable debate. Animal and cell studies have shown that dietary fat can promote metastasis \(^{22-24}\). Several mechanisms that may
underpin this association have been proposed. These include a positive association of total fat intake with IGF-I\textsuperscript{25} and androgen\textsuperscript{26} concentrations and, based on experiments in mice, a possible role in the activation of the IGF-Akt pathway and the proliferation of prostatic intraepithelial neoplasia (PIN) epithelial cells\textsuperscript{23}. Nevertheless, data from prospective studies are inconclusive\textsuperscript{2}. There are various differences between prospective studies that could account for the inconclusive findings, such as that most studies have combined grade and stage of the disease, and that the type of fatty acid rather than total amount may play a role in prostate cancer development and/or progression.

Our finding of an increased risk of advanced prostate cancer associated with higher butyric acid (4:0), caproic acid (6:0), and 4:0-10:0 combined intakes is difficult to put into context, as other prospective studies have not examined these associations. A previous survival analyses among Swedish men initially diagnosed with localized prostate cancer found that a higher intake of short chain fatty acids (4:0-10:0) may increase risk of prostate cancer death\textsuperscript{27}; myristic acid (14:0) was also related with worse prostate cancer survival in this study, but we did not find an association of this SFA with prostate cancer risk. A prospective study in Japanese men also found a positive association between myristic and palmitic acid and prostate cancer risk\textsuperscript{28}. Dairy products are the main dietary source of short chain fatty acids\textsuperscript{18}, which might be involved in prostate cancer etiology\textsuperscript{2}. Therefore, it is also possible that the observed associations are driven by other compounds present in dairy products, such as protein or calcium\textsuperscript{29}. However, when we further adjusted the multivariable-adjusted models for protein or calcium from dairy products, the significant association between butyric acid and advanced prostate cancer risk was maintained and was even a bit stronger (protein
adjustment, HR_{1SD} in calibrated intake = 1.09; 1.02-1.16; P-trend=0.016; calcium adjustment, HR_{1SD} in calibrated intake = 1.09; 1.01-1.16; P-trend=0.020). Moreover, butter is particularly high in butyric acid and it is also a good source of phytanic acid, which has been related to prostate cancer in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study 30, a cohort of Finnish male smokers. Phytanic acid is also high in fish, and as discussed below, we have also found a weak association between eicosapentaenoic acid and death from prostate cancer. However, circulating phytanic acid concentrations were not significantly associated with prostate cancer risk in the EPIC cohort 31.

A higher intake of arachidonic acid (20:4n-6c) was weakly associated with a lower risk of advanced disease, which is consistent with a previous individual participant meta-analysis of prospective studies on circulating fatty acids that found an inverse association with aggressive prostate cancer 12. However, previous prospective studies have found no association between dietary arachidonic acid and prostate cancer risk 32, 33. The possible mechanisms whereby arachidonic acid may inhibit prostate cancer progression are unknown, because previous experimental studies have suggested that the arachidonic acid pathway may be implicated in prostate cancer development and progression through its involvement in inflammation and cell growth 34. Further research is therefore needed before conclusions on risk can be drawn.

We also found some evidence that both eicosenoic (22:1n-9c) and eicosapentaenoic acid (20:5n-3c) may be associated with a higher risk of death from prostate cancer. To the best of our knowledge, no previous prospective study has looked at the association between eicosenoic acid and prostate cancer risk, but this fatty acid is often found in similar foods as
eicosapentaenoic acid (e.g. fish, and nuts and seeds)\textsuperscript{35}. Circulating eicosapentaenoic acid concentrations have been associated with a higher risk of total prostate cancer in a pooled analysis of prospective studies\textsuperscript{12} and dietary intake of eicosapentaenoic acid was associated with a higher risk of advanced and fatal prostate cancer in the NIH-AARP study\textsuperscript{36}. However, results from the Health Professionals Follow-Up Study showed that a higher intake of eicosapentaenoic acid was associated with a lower risk of total and advanced prostate cancer\textsuperscript{32}.

It was suggested in 1993 that α-linolenic acid was positively associated with advanced prostate cancer\textsuperscript{37}. However, our results, the latest meta-analysis from the WCRF/AIRC\textsuperscript{2}, and findings from a pooling study on circulating fatty acids\textsuperscript{12} do not support the hypothesis that higher intake of α-linolenic acid increases the risk of prostate cancer. Previous prospective studies have also suggested that docosapentaenoic acid (22:5n-3c) is involved in prostate cancer development\textsuperscript{12}, but we found no association between this fatty acid and prostate cancer risk. A Mendelian randomization analysis of data from up to 22,721 prostate cancer cases in the PRACTICAL consortia found no strong evidence for an association between several PUFAs, such as arachidonic acid, eicosapentaenoic acid, and docosapentaenoic acid, and overall and advanced prostate cancer risk\textsuperscript{38}.

This study has some strengths and limitations that should be considered. The major strengths include the prospective design and the large sample size, which allowed investigation of fatty acids by stage and grade of prostate cancer tumors and death from prostate cancer. This study also had reliable identification of prostate cancer cases through cancer registries and/or verified medical records. The Gleason grade was based on data available from biopsies and
surgical pathology, although there may be some misclassification because of changes in grading over time. The dietary questionnaires in all EPIC centers were validated and dietary intakes were calibrated using measures from a standardized 24-h diet recall method to correct for over and under-estimation of dietary intake 39.

A limitation of the current study was the use of dietary fatty acids intake obtained from assessment questionnaires only at recruitment, which are subject to random measurement error and changes over time, and this would likely lead to an underestimation of true associations. Although we adjusted for multiple covariates, potential unmeasured and residual confounding cannot be excluded, including having a PSA test which was not available in our cohort. In addition, some of the associations observed might be due to chance because of the number of tests performed, and if we correct for multiple testing there would not be any significant results. Moreover, because some dietary fatty acids are highly correlated, it is difficult to disentangle their independent associations with prostate cancer. It is also unclear whether the risk differences observed in our study are attributable to the individual fatty acids or if they might be driven by other compound(s) in their food sources. Finally the fatty acids food sources may vary across the European countries included in this study, for example, the primary food that contributes to oleic acid intake in the south of Europe is olive oil, whereas in some populations in the north of Europe the primary food source is meat 40.

In conclusion, intakes of individual fatty acids were not related to overall prostate cancer risk. However, our results suggest that higher intake of butyric acid may be associated with an increased risk of advanced prostate cancer. We also found a suggestive increased risk of fatal prostate cancer risk with higher intakes of eicosenoic acid and eicosapentaenoic acid. Further
prospective studies and meta-analyses are required to better understand the role of individual dietary fatty acids in prostate cancer development and progression.

Acknowledgments

The authors thank all participants in the EPIC cohort for their invaluable contribution to the study.
References

1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136: E359-86.

2. WCRF/AICR. World Cancer Research Fund International/American Institute for Cancer Research Continuous Update Project Report: Diet, Nutrition, Physical Activity, and Prostate Cancer. Available at: http://www.wcrf.org/sites/default/files/Prostate-Cancer-SLR-2014.pdf 2014.

3. Cuzick J, Thorat MA, Andriole G, Brawley OW, Brown PH, Culig Z, Eeles RA, Ford LG, Hamdy FC, Holmberg L, Ilie D, Key TJ, La Vecchia C, Lilja H, Marberger M, Meyskens FL, Minasian LM, Parker C, Parnes HL, Perner S, Rittenhouse H, Schalken J, Schmid HP, Schmitz-Drager BJ, Schroder FH, Stenzl A, Tombal B, Wilt TJ, Wolk A. Prevention and early detection of prostate cancer. Lancet Oncol 2014;15: e484-92.

4. Travis RC, Appleby PN, Martin RM, Holly JM, Albanes D, Black A, Bueno-de-Mesquita HB, Chan JM, Chen C, Chirlaque MD, Cook MB, Deschasaux M, Donovan JL, Ferrucci L, Galan P, Giles GG, Giovannucci EL, Gunter MJ, Habel LA, Hamdy FC, Helzlsouer KJ, Hercberg S, Hoover RN, Janssen JA, Kaaks R, Kubo T, Le Marchand L, Metter EJ, Mikami K, Morris JK, Neal DE, Neuhouser ML, Ozasa K, Palli D, Platz EA, Pollak MN, Price AJ, Roobol M, Schaefer C, Schenk JM, Severi G, Stampfer MJ, Stattin P, Tamakoshi A, Tangen CM, Touvier M, Wald NJ, Weiss NS, Zeigler RG, Key TJ, Allen NE.
A meta-analysis of individual participant data reveals an association between circulating levels of IGF-I and prostate cancer risk. Cancer Res 2016;76: 2288-300.

5. Perez-Cornago A, Appleby PN, Pischon T, Tsilidis KK, Tjonneland A, Olsen A, Overvad K, Kaaks R, Kuhn T, Boeing H, Steffen A, Trichopoulou A, Lagiou P, Kritikou M, Krogh V, Palli D, Sacerdote C, Tumino R, Bueno-de-Mesquita HB, Agudo A, Larranaga N, Molina-Portillo E, Barricarte A, Chirlaque MD, Quiros JR, Stattin P, Haggstrom C, Wareham N, Khaw KT, Schmidt JA, Gunter M, Freisling H, Aune D, Ward H, Riboli E, Key TJ, Travis RC. Tall height and obesity are associated with an increased risk of aggressive prostate cancer: results from the EPIC cohort study. BMC Med 2017;15: 115.

6. Lee J, Demissie K, Lu SE, Rhoads GG. Cancer incidence among Korean-American immigrants in the United States and native Koreans in South Korea. Cancer Control 2007;14: 78-85.

7. Wu J, Wilson KM, Stampfer MJ, Willett WC, Giovannucci EL. A 24-year prospective study of dietary alpha-linolenic acid and lethal prostate cancer. Int J Cancer 2018;142: 2207-14.

8. Richman EL, Kenfield SA, Chavarro JE, Stampfer MJ, Giovannucci EL, Willett WC, Chan JM. Fat intake after diagnosis and risk of lethal prostate cancer and all-cause mortality. JAMA Intern Med 2013;173: 1318-26.
9. Markozannes G, Tzoulaki I, Karli D, Evangelou E, Ntzani E, Gunter MJ, Norat T, Ioannidis JP, Tsilidis KK. Diet, body size, physical activity and risk of prostate cancer: An umbrella review of the evidence. Eur J Cancer 2016;69: 61-9.

10. Zong G, Li YP, Wanders AJ, Alsem M, Zock PL, Willett WC, Hu FB, Sun Q. Intake of individual saturated fatty acids and risk of coronary heart disease in US men and women: two prospective longitudinal cohort studies. Brit Med J 2016;355.

11. Wang DD, Li Y, Chiuve SE, Stampfer MJ, Manson JE, Rimm EB, Willett WC, Hu FB. Association of specific dietary fats with total and cause-specific mortality. JAMA Intern Med 2016;176: 1134-45.

12. Crowe FL, Appleby PN, Travis RC, Barnett M, Brasky TM, Bueno-de-Mesquita HB, Chajes V, Chavarro JE, Chirlaque MD, English DR, Gibson RA, Giles GG, Goodman GE, Henning SM, Kaaks R, King IB, Kolonel LN, Kristal AR, Neuhaus ML, Park SY, Severi G, Siddiq A, Stampfer MJ, Stattin P, Tangen CM, Tjonneland A, Trichopoulos D, Tumino R, Wilkens LR, Key TJ, Allen NE, Endogenous Hormones NB, Prostate Cancer Collaborative G. Circulating fatty acids and prostate cancer risk: individual participant meta-analysis of prospective studies. J Natl Cancer Inst 2014;106.

13. Riboli E, Hunt KJ, Slimani N, Ferrari P, Norat T, Fahey M, Charrondiere UR, Hemon B, Casagrande C, Vignat J, Overvad K, Tjonneland A, Clavel-Chapelon F, Thiebaut A, Wahrendorf J, Boeing H, Trichopoulos D, Trichopoulos A, Vineis P, Palli D, Bueno-De-Mesquita HB, Peeters PH, Lund E, Engeset D, Gonzalez CA, Barricarte A, Berglund G, Hallmans G, Day NE, Key TJ, Kaaks R, Saracci R. European Prospective Investigation into
Cancer and Nutrition (EPIC): study populations and data collection. Public Health Nutr 2002;5: 1113-24.

14. Ferrari P, Slimani N, Ciampi A, Trichopoulou A, Naska A, Lauria C, Veglia F, Bueno-de-Mesquita HB, Ocke MC, Brustad M, Braaten T, Jose Tormo M, Amiano P, Mattisson I, Johansson G, Welch A, Davey G, Overvad K, Tjonneland A, Clavel-Chapelon F, Thiebaut A, Linseisen J, Boeing H, Hemon B, Riboli E. Evaluation of under- and overreporting of energy intake in the 24-hour diet recalls in the European Prospective Investigation into Cancer and Nutrition (EPIC). Public Health Nutr 2002;5: 1329-45.

15. Margetts BM, Pietinen P. European Prospective Investigation into Cancer and Nutrition: validity studies on dietary assessment methods. Int J Epidemiol 1997;26 Suppl 1: S1-5.

16. Ma J, Stampfer MJ, Gann PH, Hough HL, Giovannucci E, Kelsey KT, Hennekens CH, Hunter DJ. Vitamin D receptor polymorphisms, circulating vitamin D metabolites, and risk of prostate cancer in United States physicians. Cancer Epidemiol Biomarkers Prev 1998;7: 385-90.

17. Willett W. Implications of total energy intake for epidemiologic analyses. Nutritional epidemiology. 3rd ed. Oxford University Press. 2013.

18. German JB, Dillard CJ. Saturated fats: what dietary intake? Am J Clin Nutr 2004;80: 550-9.
19. WHO. International statistical classification of diseases and related health problems. 10th revision. Available from: http://apps.who.int/classifications/icd10/browse/2010/en (cited 01 April 2016).

20. Wareham NJ, Jakes RW, Rennie KL, Schuit J, Mitchell J, Hennings S, Day NE. Validity and repeatability of a simple index derived from the short physical activity questionnaire used in the European Prospective Investigation into Cancer and Nutrition (EPIC) study. Public Health Nutr 2003;6: 407-13.

21. Smith-Warner SA, Spiegelman D, Ritz J, Albanes D, Beeson WL, Bernstein L, Berrino F, van den Brandt PA, Buring JE, Cho E, Colditz GA, Folsom AR, Freudenheim JL, Giovannucci E, Goldbohm RA, Graham S, Harnack L, Horn-Ross PL, Krogh V, Leitzmann MF, McCullough ML, Miller AB, Rodriguez C, Rohan TE, Schatzkin A, Shore R, Virtanen M, Willett WC, Wolk A, Zeleniuch-Jacquotte A, Zhang SM, Hunter DJ. Methods for pooling results of epidemiologic studies: the Pooling Project of Prospective Studies of Diet and Cancer. Am J Epidemiol 2006;163: 1053-64.

22. Pascual G, Avgustinova A, Mejetta S, Martin M, Castellanos A, Attolini CS, Berenguer A, Prats N, Toll A, Hueto JA, Bescos C, Di Croce L, Benitah SA. Targeting metastasis-initiating cells through the fatty acid receptor CD36. Nature 2017;541: 41-5.

23. Kobayashi N, Barnard RJ, Said J, Hong-Gonzalez J, Corman DM, Ku M, Doan NB, Gui D, Elashoff D, Cohen P, Aronson WJ. Effect of low-fat diet on development of prostate cancer and Akt phosphorylation in the Hi-Myc transgenic mouse model. Cancer Res 2008;68: 3066-73.
24. Venkateswaran V, Klotz LH. Diet and prostate cancer: mechanisms of action and implications for chemoprevention. Nat Rev Urol 2010;7: 442-53.

25. Kaklamani VG, Linos A, Kaklamani E, Markaki I, Koumantaki Y, Mantzoros CS. Dietary fat and carbohydrates are independently associated with circulating insulin-like growth factor 1 and insulin-like growth factor-binding protein 3 concentrations in healthy adults. J Clin Oncol 1999;17: 3291-8.

26. Dorgan JF, Judd JT, Longcope C, Brown C, Schatzkin A, Clevelence BA, Campbell WS, Nair PP, Franz C, Kahle L, Taylor PR. Effects of dietary fat and fiber on plasma and urine androgens and estrogens in men: a controlled feeding study. Am J Clin Nutr 1996;64: 850-5.

27. Epstein MM, Kasperzyk JL, Mucci LA, Giovannucci E, Price A, Wolk A, Hakansson N, Fall K, Andersson SO, Andren O. Dietary fatty acid intake and prostate cancer survival in Orebro County, Sweden. Am J Epidemiol 2012;176: 240-52.

28. Kurahashi N, Inoue M, Iwasaki M, Sasazuki S, Tsugane AS, Japan Public Health Center-Based Prospective Study G. Dairy product, saturated fatty acid, and calcium intake and prostate cancer in a prospective cohort of Japanese men. Cancer Epidemiol Biomarkers Prev 2008;17: 930-7.

29. Allen NE, Key TJ, Appleby PN, Travis RC, Roddam AW, Tjonneland A, Johnsen NF, Overvad K, Linseisen J, Rohrmann S, Boeing H, Pischon T, Bueno-de-Mesquita HB, Kiemeney L, Tagliabue G, Palli D, Vineis P, Tumino R, Trichopoulou A, Kassapa C,
Trichopoulos D, Ardanaz E, Larranaga N, Tormo MJ, Gonzalez CA, Quiros JR, Sanchez MJ, Bingham S, Khaw KT, Manjer J, Berglund G, Stattin P, Hallmans G, Slimani N, Ferrari P, Rinaldi S, Riboli E. Animal foods, protein, calcium and prostate cancer risk: the European Prospective Investigation into Cancer and Nutrition. Br J Cancer 2008;98: 1574-81.

30. Wright ME, Bowen P, Virtamo J, Albanes D, Gann PH. Estimated phytanic acid intake and prostate cancer risk: a prospective cohort study. Int J Cancer 2012;131: 1396-406.

31. Price AJ, Allen NE, Appleby PN, Crowe FL, Jenab M, Rinaldi S, Slimani N, Kaaks R, Rohrmann S, Boeing H, Pischon T, Benetou V, Naska A, Trichopoulou A, Palli D, Sieri S, Tumino R, Vineis P, Bueno-de-Mesquita HB, Donate I, Gonzalez CA, Sanchez MJ, Chirlaque MD, Ardanaz E, Larranaga N, Khaw KT, Rodwell S, Gallo V, Michaud DS, Riboli E, Key TJ. Plasma phytanic acid concentration and risk of prostate cancer: results from the European Prospective Investigation into Cancer and Nutrition. Am J Clin Nutr 2010;91: 1769-76.

32. Leitzmann MF, Stampfer MJ, Michaud DS, Augustsson K, Colditz GC, Willett WC, Giovannucci EL. Dietary intake of n-3 and n-6 fatty acids and the risk of prostate cancer. Am J Clin Nutr 2004;80: 204-16.

33. Schuurman AG, van den Brandt PA, Dorant E, Brants HA, Goldbohm RA. Association of energy and fat intake with prostate carcinoma risk: results from The Netherlands Cohort Study. Cancer 1999;86: 1019-27.
34. Patel MI, Kurek C, Dong Q. The arachidonic acid pathway and its role in prostate cancer development and progression. J Urol 2008;179: 1668-75.

35. US Department of Agriculture Food Composition Databases. Available at: https://ndb.nal.usda.gov/ndb/nutrients/index (Access 08 January 2019).

36. Pelser C, Mondul AM, Hollenbeck AR, Park Y. Dietary fat, fatty acids, and risk of prostate cancer in the NIH-AARP diet and health study. Cancer Epidemiol Biomarkers Prev 2013;22: 697-707.

37. Giovannucci E, Rimm EB, Colditz GA, Stampfer MJ, Ascherio A, Chute CG, Willett WC. A prospective study of dietary fat and risk of prostate cancer. J Natl Cancer Inst 1993;85: 1571-9.

38. Khankari NK, Murff HJ, Zeng C, Wen W, Eeles RA, Easton DF, Kote-Jarai Z, Al Olama AA, Benlloch S, Muir K, Giles GG, Wiklund F, Gronberg H, Haiman CA, Schleutker J, Nordestgaard BG, Travis RC, Donovan JL, Pashayan N, Khaw KT, Stanford JL, Blot WJ, Thibodeau SN, Maier C, Kibel AS, Cybulski C, Cannon-Albright L, Brenner H, Park J, Kaneva R, Batra J, Teixeira MR, Pandha H, Zheng W, consortium P. Polyunsaturated fatty acids and prostate cancer risk: a Mendelian randomisation analysis from the PRACTICAL consortium. Br J Cancer 2016;115: 624-31.

39. Margetts BM, Pietinen P. European Prospective Investigation into Cancer and Nutrition: Validity studies on dietary assessment methods. Int J Epidemiol 1997;26: S1-S5.
40. Pot GK, Pryne CJ, Roberts C, Olson A, Nicholson SK, Whitton C, Teucher B, Bates B, Henderson H, Pigott S, Swan G, Stephen AM. National Diet and Nutrition Survey: fat and fatty acid intake from the first year of the rolling programme and comparison with previous surveys. Br J Nutr 2012;107: 405-15.
Table 1. Baseline characteristics of 142,239 men in EPIC (1992-2013) according to observed SFAs, MUFAs and PUFAs intakes.

|                           | Fifths of observed SFAs intake |       | Fifths of observed MUFAs intake |       | Fifths of observed PUFAs intake |       |
|---------------------------|--------------------------------|-------|--------------------------------|-------|--------------------------------|-------|
|                           | 1                              | 3     | 5                              | 1     | 3                              | 5     |
| No. of men                | 28448                          | 28448 | 28447                          | 28448 | 28448                          | 28447 |
| Age at recruitment\(^1\), y| 52.2 (9.7)                     | 51.7 (10.3) | 51.1 (10.3)                    | 52.8 (10.6) | 51.8 (9.8) | 50.6 (10.5) |
| Age at diagnosis\(^1\), y  | 67.8 (6.4)                     | 68.1 (6.8) | 67.5 (6.9)                     | 68.7 (6.8) | 68.0 (6.5) | 66.9 (6.7) |
| Smoking, n (%)            |                                |       |                                | 52.3 (8.5) | 51.7 (10.1) | 51.0 (11.4) |
|   Never                   | 8990 (31.6)                    | 9475 (33.3) | 9526 (33.5)                    | 9958 (35.0) | 9713 (34.1) | 8175 (28.7) |
|   Former                  | 10650 (37.4)                   | 10266 (36.1) | 9838 (34.6)                    | 11130 (39.1) | 10299 (36.2) | 9400 (33.0) |
|   Current                 | 8479 (29.8)                    | 8281 (29.1) | 8704 (30.6)                    | 6979 (24.5) | 8137 (28.6) | 10193 (35.8) |
| Educational level, n (%)  |                                |       |                                | 9375 (33.0) | 7892 (27.7) | 8324 (29.3) |
|   No degree               | 20722 (72.8)                   | 20560 (72.3) | 18919 (66.5)                   | 18064 (63.5) | 19806 (69.6) | 22702 (79.8) |
|   Degree                  | 6638 (23.3)                    | 7156 (25.2) | 8918 (31.3)                    | 8724 (30.7) | 7996 (28.1) | 5552 (19.5) |
| Physical activity, n (%)  |                                |       |                                | 6887 (24.2) | 8014 (28.2) | 7139 (25.1) |
|   Inactive                | 5527 (19.4)                    | 5134 (18.0) | 5539 (19.5)                    | 5366 (18.9) | 4745 (16.7) | 6816 (24.0) |
|   Moderately inactive     | 8502 (29.9)                    | 8721 (30.7) | 8854 (31.1)                    | 8426 (29.6) | 8770 (30.8) | 8782 (30.9) |
|   Moderately active       | 6950 (24.4)                    | 6793 (23.9) | 6958 (24.5)                    | 6773 (23.8) | 6906 (24.3) | 7013 (24.7) |
|   Active                  | 7190 (25.3)                    | 7088 (24.9) | 6320 (22.2)                    | 7297 (25.7) | 7271 (25.6) | 5570 (19.6) |
| Diabetes at baseline, n (%)|                                |       |                                | 7272 (25.6) | 6870 (24.1) | 6516 (22.9) |
|   No                      | 26578 (93.4)                   | 26848 (94.4) | 26869 (94.5)                   | 26618 (93.6) | 26937 (94.7) | 26610 (93.5) |
|   Yes                     | 1203 (4.2)                     | 923 (3.2) | 1064 (3.7)                     | 1024 (3.6) | 864 (3.0) | 1459 (5.1) |
| Marital status, n (%)     |                                |       |                                | 981 (3.4) | 1104 (3.9) | 961 (3.4) |
|   Married                 | 11222 (39.4)                   | 16441 (57.8) | 19193 (67.5)                   | 14234 (50.0) | 15587 (54.8) | 18378 (64.6) |
|   Not married             | 2944 (10.3)                    | 3624 (12.7) | 4983 (17.5)                    | 4210 (14.8) | 3707 (13.0) | 3117 (11.0) |
| Height\(^1\), cm          | 173.1 (7.4)                    | 175.0 (7.3) | 175.8 (7.1)                    | 175.4 (7.0) | 175.5 (7.2) | 172.2 (7.5) |
| BMI\(^1\), kg/m\(^2\)     | 26.8 (3.7)                     | 26.4 (3.6) | 26.3 (3.7)                     | 26.3 (3.7) | 26.2 (3.5) | 27.3 (3.8) |

This article is protected by copyright. All rights reserved.
| Total energy intake¹, Kcal/d | 2,289 (641) | 2,426 (650) | 2,508 (701) | 2,232 (623) | 2,442 (641) | 2,500 (703) | 2,431 (679) | 2,391 (648) | 2,438 (676) |
|-----------------------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|

Percentages do not match due to missing data. Fifths calculated from g/1000 kcal of each fatty acid.

¹ Values are means (SD).

Abbreviations: BMI, body mass index; MUFAs, monounsaturated fatty acids; PUFAs, polyunsaturated fatty acids; SFAs, saturated fatty acids.
Table 2. Multivariable-adjusted hazard ratios (95 % CI) for prostate cancer per 1-SD increase of total fat and individual saturated fatty acids intake in 142,239 men in EPIC (1992-2013).

|                      | No. cases | HR (95 % CI) | P trend | P het |
|----------------------|-----------|--------------|---------|-------|
| **Total Fat**        |           |              |         |       |
| Total prostate cancer| 7036      | 0.99 (0.96 - 1.02) | 0.389   |       |
| Grade                |           |              |         |       |
| Low                  | 3757      | 0.95 (0.91 - 1.00) | 0.038   |       |
| High                 | 726       | 1.04 (0.95 - 1.14) | 0.419   | 0.084 |
| Stage                |           |              |         |       |
| Localized            | 2641      | 0.98 (0.93 - 1.04) | 0.544   |       |
| Advanced             | 1389      | 1.01 (0.95 - 1.08) | 0.708   | 0.392 |
| Fatal prostate cancer| 936       | 1.00 (0.92 - 1.08) | 0.965   |       |
| **Total SFAs**       |           |              |         |       |
| Total prostate cancer| 7036      | 1.00 (0.96 - 1.03) | 0.850   |       |
| Grade                |           |              |         |       |
| Low                  | 3757      | 0.96 (0.92 - 1.01) | 0.144   |       |
| High                 | 726       | 1.07 (0.96 - 1.19) | 0.234   | 0.041 |
| Stage                |           |              |         |       |
| Localized            | 2641      | 0.97 (0.91 - 1.02) | 0.239   |       |
| Advanced             | 1389      | 1.05 (0.97 - 1.13) | 0.257   | 0.052 |
| Fatal prostate cancer| 936       | 1.02 (0.92 - 1.12) | 0.723   |       |
| **Butyric acid (4:0)**|          |              |         |       |
| Total prostate cancer| 7036      | 1.01 (0.98 - 1.04) | 0.496   |       |
| Grade                |           |              |         |       |
| Low                  | 3757      | 0.99 (0.95 - 1.03) | 0.724   |       |
| High                 | 726       | 1.07 (0.97 - 1.17) | 0.162   | 0.035 |
| Stage                |           |              |         |       |
| Localized            | 2641      | 0.96 (0.92 - 1.01) | 0.135   |       |
| Advanced             | 1389      | 1.08 (1.01 - 1.15) | 0.026   | 0.004 |
| Fatal prostate cancer| 936       | 1.02 (0.94 - 1.12) | 0.599   |       |
| **Caproic acid (6:0)**|          |              |         |       |
| Total prostate cancer| 7036      | 1.00 (0.97 - 1.04) | 0.819   |       |
| Grade                |           |              |         |       |
| Low                  | 3757      | 0.98 (0.94 - 1.02) | 0.380   |       |
| High                 | 726       | 1.06 (0.97 - 1.16) | 0.198   | 0.034 |
| Stage                |           |              |         |       |
| Localized            | 2641      | 0.96 (0.91 - 1.00) | 0.071   |       |
| Advanced             | 1389      | 1.06 (1.00 - 1.13) | 0.053   | 0.006 |
| Fatal prostate cancer| 936       | 1.03 (0.95 - 1.12) | 0.476   |       |
| **Caprylic acid (8:0)**|          |              |         |       |
| Total prostate cancer| 7036      | 1.00 (0.97 - 1.03) | 0.937   |       |
| Grade                |           |              |         |       |
| Low                  | 3757      | 0.97 (0.93 - 1.01) | 0.156   |       |
| High                 | 726       | 1.04 (0.95 - 1.14) | 0.394   | 0.068 |
| Stage                |           |              |         |       |
| Localized            | 2641      | 0.95 (0.91 - 1.00) | 0.042   |       |
| Advanced             | 1389      | 1.05 (0.99 - 1.12) | 0.122   | 0.013 |
| Fatal prostate cancer| 936       | 1.05 (0.97 - 1.13) | 0.272   |       |
| **Capric acid (10:0)**|          |              |         |       |
| Total prostate cancer| 7036      | 1.01 (0.97 - 1.04) | 0.775   |       |
| Grade                |           |              |         |       |
| Low                  | 3757      | 0.98 (0.94 - 1.03) | 0.397   |       |
| High                 | 726       | 1.06 (0.95 - 1.17) | 0.317   | 0.072 |
| Stage                |           |              |         |       |
| Localized            | 2641      | 0.96 (0.90 - 1.01) | 0.116   |       |
| Advanced             | 1389      | 1.06 (0.99 - 1.14) | 0.093   | 0.023 |
| Fatal prostate cancer| 936       | 1.04 (0.94 - 1.14) | 0.481   |       |
| **Lauric acid (12:0)**|          |              |         |       |

This article is protected by copyright. All rights reserved.
|                  | 7036 | 1.00 (0.97 - 1.04) | 0.791 |
|------------------|------|-------------------|-------|
| **Total prostate cancer** |      |                   |       |
| **Grade**        |      |                   |       |
| Low              | 3757 | 0.98 (0.93 - 1.02) | 0.333 |
| High             | 726  | 1.07 (0.97 - 1.19) | 0.182 | 0.102 |
| **Stage**        |      |                   |       |
| Localized        | 2641 | 0.96 (0.91 - 1.01) | 0.153 |
| Advanced         | 1389 | 1.07 (0.99 - 1.14) | 0.079 | 0.078 |
| **Fatal prostate cancer** | 936  | 1.06 (0.96 - 1.17) | 0.253 |
| **Myristic acid (14:0)** |      |                   |       |
| Total prostate cancer | 7036 | 1.00 (0.97 - 1.04) | 0.916 |
| Grade            |      |                   |       |
| Low              | 3757 | 0.97 (0.93 - 1.02) | 0.208 |
| High             | 726  | 1.06 (0.96 - 1.17) | 0.265 | 0.028 |
| **Stage**        |      |                   |       |
| Localized        | 2641 | 0.96 (0.91 - 1.01) | 0.113 |
| Advanced         | 1389 | 1.06 (0.98 - 1.14) | 0.129 | 0.013 |
| **Fatal prostate cancer** | 936  | 1.04 (0.95 - 1.14) | 0.426 |
| **Pentadecanoic acid (15:0)** |      |                   |       |
| Total prostate cancer | 7036 | 0.98 (0.94 - 1.01) | 0.152 |
| Grade            |      |                   |       |
| Low              | 3757 | 0.99 (0.94 - 1.04) | 0.618 |
| High             | 726  | 0.93 (0.84 - 1.03) | 0.146 | 0.427 |
| **Stage**        |      |                   |       |
| Localized        | 2641 | 0.96 (0.91 - 1.02) | 0.212 |
| Advanced         | 1389 | 0.97 (0.91 - 1.04) | 0.430 | 0.511 |
| **Fatal prostate cancer** | 936  | 0.97 (0.89 - 1.05) | 0.410 |
| **Palmitic acid (16:0)** |      |                   |       |
| Total prostate cancer | 7036 | 0.99 (0.95 - 1.03) | 0.627 |
| Grade            |      |                   |       |
| Low              | 3757 | 0.96 (0.91 - 1.01) | 0.104 |
| High             | 726  | 1.06 (0.95 - 1.19) | 0.282 | 0.064 |
| **Stage**        |      |                   |       |
| Localized        | 2641 | 0.97 (0.91 - 1.03) | 0.324 |
| Advanced         | 1389 | 1.03 (0.95 - 1.12) | 0.436 | 0.131 |
| **Fatal prostate cancer** | 936  | 1.02 (0.92 - 1.12) | 0.709 |
| **Stearic acid (18:0)** |      |                   |       |
| Total prostate cancer | 7036 | 0.99 (0.96 - 1.02) | 0.549 |
| Grade            |      |                   |       |
| Low              | 3757 | 0.98 (0.94 - 1.03) | 0.442 |
| High             | 726  | 1.03 (0.93 - 1.13) | 0.562 | 0.130 |
| **Stage**        |      |                   |       |
| Localized        | 2641 | 0.96 (0.92 - 1.01) | 0.141 |
| Advanced         | 1389 | 1.06 (0.99 - 1.13) | 0.099 | 0.036 |
| **Fatal prostate cancer** | 936  | 0.98 (0.90 - 1.08) | 0.738 |
| **Arachidic acid (20:0)** |      |                   |       |
| Total prostate cancer | 7036 | 0.99 (0.95 - 1.03) | 0.628 |
| Grade            |      |                   |       |
| Low              | 3757 | 0.96 (0.90 - 1.01) | 0.118 |
| High             | 726  | 1.06 (0.94 - 1.20) | 0.349 | 0.087 |
| **Stage**        |      |                   |       |
| Localized        | 2641 | 0.97 (0.90 - 1.04) | 0.357 |
| Advanced         | 1389 | 1.04 (0.95 - 1.14) | 0.387 | 0.117 |
| **Fatal prostate cancer** | 936  | 0.99 (0.89 - 1.10) | 0.799 |

This article is protected by copyright. All rights reserved.
|                                | HR (95% CI) |
|--------------------------------|-------------|
| Localized                      | 1.01 (0.94 - 1.10) |
| Advanced                       | 0.96 (0.86 - 1.07) |
| Fatal prostate cancer          | 0.89 (0.77 - 1.04) |
| **Behenic acid (22:0)**        |             |
| Total prostate cancer Grade    |              |
| Low                            | 0.99 (0.94 - 1.04) |
| High                           | 0.90 (0.76 - 1.06) |
| Stage                          |              |
| Localized                      | 1.01 (0.95 - 1.03) |
| Advanced                       | 0.94 (0.85 - 1.04) |
| Fatal prostate cancer          | 0.90 (0.77 - 1.04) |
| **4:0-10:0**                   |             |
| Total prostate cancer Grade    |              |
| Low                            | 0.98 (0.94 - 1.03) |
| High                           | 1.06 (0.96 - 1.16) |
| Stage                          |              |
| Localized                      | 0.96 (0.91 - 1.01) |
| Advanced                       | 1.07 (1.00 - 1.14) |
| Fatal prostate cancer          | 1.03 (0.95 - 1.12) |
| **12:0-14:0**                  |             |
| Total prostate cancer Grade    |              |
| Low                            | 0.97 (0.93 - 1.02) |
| High                           | 1.07 (0.96 - 1.18) |
| Stage                          |              |
| Localized                      | 0.96 (0.91 - 1.01) |
| Advanced                       | 1.06 (0.99 - 1.14) |
| Fatal prostate cancer          | 1.05 (0.96 - 1.16) |

Cox regression analysis. All models are stratified by centre and age at recruitment and adjusted for age (underlying time variable), educational level (no degree, degree or unknown), smoking status (never, former, current or unknown), marital status (married, not married, unknown), diabetes (yes, no, unknown), physical activity (inactive, moderately inactive, moderately active, active, unknown), height (<170, 170–174, 175–179, ≥ 180 cm or unknown), body mass index (<22.5, 22.5–24.9, 25–29.9, ≥ 30 kg/m² or unknown), and total energy intake (fifths).

1 HR (95% CI) estimated per 1-SD increase in fatty acids intake.
2 Linear trends for HRs estimates over a continuous scale of the individual fatty acid.
3 *P*-value from test for heterogeneity for the associations of intake the individual fatty acids with risk of prostate cancer categorized according to prostate tumour grade (low-intermediate or high) and stage (localized or advanced).

Low-intermediate grade (Gleason score of <8, or grade coded as well, moderately, or poorly differentiated). High grade (Gleason score of ≥ 8, or grade coded as undifferentiated). Localized stage (TNM staging score of T0-T2 and N0/Nx and M0, or stage coded in the recruitment centre as localized). Advanced stage (T3-T4 and/or N1-N3 and/or M1, and/or stage coded in the recruitment centre as metastatic).

Abbreviation: SFAs saturated fatty acids.
Table 3. Multivariable-adjusted hazard ratios (95 % CI) for prostate cancer per 1-SD increase of individual monounsaturated fatty acids intake in 142,239 men in EPIC (1992-2013).

|                | No. cases | HR (95 % CI) | P trend | P het |
|----------------|-----------|--------------|---------|-------|
| **Total MUFAs**|           |              |         |       |
| Total prostate cancer | 7036 | 0.98 (0.93 - 1.02) | 0.303   |       |
| Grade          |           |              |         |       |
| Low            | 3757      | 0.95 (0.90 - 1.01) | 0.121   |       |
| High           | 726       | 1.04 (0.91 - 1.18) | 0.613   | 0.411 |
| Stage          |           |              |         |       |
| Localized      | 2641      | 1.00 (0.93 - 1.08) | 0.991   |       |
| Advanced       | 1389      | 1.01 (0.91 - 1.11) | 0.920   | 0.942 |
| Fatal prostate cancer | 936 | 0.98 (0.87 - 1.10) | 0.676   |       |
| **Palmitoleic acid (16:1n-7c)** |           |              |         |       |
| Total prostate cancer | 7036 | 1.00 (0.94 - 1.05) | 0.893   |       |
| Grade          |           |              |         |       |
| Low            | 3757      | 0.96 (0.89 - 1.04) | 0.353   |       |
| High           | 726       | 1.08 (0.91 - 1.28) | 0.372   | 0.317 |
| Stage          |           |              |         |       |
| Localized      | 2641      | 1.01 (0.92 - 1.11) | 0.779   |       |
| Advanced       | 1389      | 1.02 (0.91 - 1.15) | 0.742   | 0.731 |
| Fatal prostate cancer | 936 | 1.06 (0.91 - 1.23) | 0.446   |       |
| **Oleic acid (18:1n-9c)** |           |              |         |       |
| Total prostate cancer | 7036 | 0.98 (0.94 - 1.03) | 0.405   |       |
| Grade          |           |              |         |       |
| Low            | 3757      | 0.96 (0.90 - 1.02) | 0.182   |       |
| High           | 726       | 1.03 (0.89 - 1.18) | 0.686   | 0.517 |
| Stage          |           |              |         |       |
| Localized      | 2641      | 0.99 (0.92 - 1.07) | 0.847   |       |
| Advanced       | 1389      | 1.02 (0.92 - 1.13) | 0.777   | 0.945 |
| Fatal prostate cancer | 936 | 0.98 (0.87 - 1.11) | 0.744   |       |
| **Eicosenoic acid (20:1n-9c)** |           |              |         |       |
| Total prostate cancer | 7036 | 1.01 (0.98 - 1.03) | 0.540   |       |
| Grade          |           |              |         |       |
| Low            | 3757      | 0.98 (0.94 - 1.02) | 0.283   |       |
| High           | 726       | 1.05 (0.99 - 1.12) | 0.094   | 0.174 |
| Stage          |           |              |         |       |
| Localized      | 2641      | 1.00 (0.95 - 1.04) | 0.932   |       |
| Advanced       | 1389      | 1.02 (0.97 - 1.06) | 0.512   | 0.550 |
| Fatal prostate cancer | 936 | 1.05 (1.00 - 1.11) | 0.048   |       |
| **Erucic acid (22:1n-9c)** |           |              |         |       |
| Total prostate cancer | 7036 | 1.01 (0.98 - 1.03) | 0.500   |       |
| Grade          |           |              |         |       |
| Low            | 3757      | 0.97 (0.93 - 1.02) | 0.262   |       |
| High           | 726       | 1.06 (0.99 - 1.12) | 0.091   | 0.129 |
| Stage          |           |              |         |       |
| Localized      | 2641      | 1.00 (0.95 - 1.04) | 0.865   |       |
| Advanced       | 1389      | 1.02 (0.98 - 1.07) | 0.363   | 0.313 |
| Fatal prostate cancer | 936 | 1.05 (1.00 - 1.11) | 0.055   |       |

Cox regression analysis. All models are stratified by centre and age at recruitment and adjusted for age (underlying time variable), educational level (no degree, degree or unknown), smoking status (never, former, current or unknown), marital status (married, not married, unknown), diabetes (yes, no, unknown), physical activity (inactive, moderately inactive, moderately active, active, unknown), height (<170, 170–174, 175–179, ≥ 180 cm or unknown), body mass index (<22.5, 22.5–24.9, 25–29.9, ≥ 30 kg/m² or unknown), and total energy intake (fifths).

1 HR (95% CI) estimated per 1-SD increase in fatty acids intake.

2 Linear trends for HRs estimates over a continuous scale of the individual fatty acid.

3 P-value from test for heterogeneity for the associations of intake the individual fatty acids with risk of prostate cancer categorized according to prostate tumour grade (low-intermediate or high) and stage (localized or advanced).
Low-intermediate grade (Gleason score of <8, or grade coded as well, moderately, or poorly differentiated). High grade (Gleason score of ≥ 8, or grade coded as undifferentiated). Localized stage (TNM staging score of T0-T2 and N0/Nx and M0, or stage coded in the recruitment centre as localized). Advanced stage (T3-T4 and/or N1-N3 and/or M1, and/or stage coded in the recruitment centre as metastatic).

Abbreviations: MUFAs, monounsaturated fatty acids.
| Table 4: Multivariable-adjusted hazard ratios (95% CI) for prostate cancer per 1-SD increase of individual polyunsaturated fatty acids intake in 142,239 men in EPIC (1992–2013). |
|-----------------------------------------------|
| **Calibrated** | **No. cases** | **HR (95% CI)** | **P trend** | **P het** |
| **Total PUFAs** | | | | |
| Total prostate cancer | 7036 | 0.98 (0.95 - 1.02) | 0.340 |
| Grade | | | | |
| Low | 3757 | 0.96 (0.91 - 1.01) | 0.086 |
| High | 726 | 1.00 (0.91 - 1.11) | 0.925 | 0.508 |
| Stage | | | | |
| Localized | 2641 | 0.99 (0.94 - 1.05) | 0.830 |
| Advanced | 1389 | 0.97 (0.90 - 1.05) | 0.434 | 0.777 |
| Fatal prostate cancer | 936 | 0.99 (0.90 - 1.09) | 0.836 |
| **Linoleic acid (18:2n-6c)** | | | | |
| Total prostate cancer | 7036 | 0.98 (0.95 - 1.02) | 0.311 |
| Grade | | | | |
| Low | 3757 | 0.96 (0.91 - 1.00) | 0.063 |
| High | 726 | 1.01 (0.91 - 1.12) | 0.857 | 0.450 |
| Stage | | | | |
| Localized | 2641 | 0.99 (0.93 - 1.05) | 0.678 |
| Advanced | 1389 | 0.97 (0.90 - 1.05) | 0.440 | 0.824 |
| Fatal prostate cancer | 936 | 0.99 (0.90 - 1.08) | 0.822 |
| **α-Linolenic acid (18:3n-3c)** | | | | |
| Total prostate cancer | 7036 | 0.99 (0.95 - 1.02) | 0.502 |
| Grade | | | | |
| Low | 3757 | 0.97 (0.92 - 1.03) | 0.270 |
| High | 726 | 1.01 (0.91 - 1.13) | 0.817 | 0.514 |
| Stage | | | | |
| Localized | 2641 | 0.98 (0.92 - 1.05) | 0.602 |
| Advanced | 1389 | 1.00 (0.93 - 1.08) | 0.907 | 0.434 |
| Fatal prostate cancer | 936 | 0.99 (0.90 - 1.09) | 0.839 |
| **Arachidonic acid (20:4n-6c)** | | | | |
| Total prostate cancer | 7036 | 0.99 (0.95 - 1.03) | 0.638 |
| Grade | | | | |
| Low | 3757 | 0.97 (0.92 - 1.03) | 0.387 |
| High | 726 | 0.94 (0.82 - 1.08) | 0.381 | 0.404 |
| Stage | | | | |
| Localized | 2641 | 1.05 (0.97 - 1.13) | 0.213 |
| Advanced | 1389 | 0.91 (0.82 - 1.01) | 0.072 | 0.021 |
| Fatal prostate cancer | 936 | 1.03 (0.92 - 1.15) | 0.636 |
| **Eicosapentaenoic acid (20:5n-3c)** | | | | |
| Total prostate cancer | 7036 | 1.02 (0.99 - 1.04) | 0.272 |
| Grade | | | | |
| Low | 3757 | 1.01 (0.96 - 1.05) | 0.762 |
| High | 726 | 0.99 (0.92 - 1.08) | 0.895 | 0.660 |
| Stage | | | | |
| Localized | 2641 | 1.02 (0.98 - 1.07) | 0.343 |
| Advanced | 1389 | 1.01 (0.95 - 1.07) | 0.831 | 0.601 |
| Fatal prostate cancer | 936 | 1.07 (1.00 - 1.14) | 0.045 |
| **Docosapentaenoic acid (22:5n-3c)** | | | | |
| Total prostate cancer | 7036 | 1.00 (0.97 - 1.03) | 0.989 |
| Grade | | | | |
| Low | 3757 | 1.00 (0.96 - 1.04) | 0.809 |
| High | 726 | 0.97 (0.90 - 1.05) | 0.454 | 0.357 |
| Stage | | | | |
| Localized | 2641 | 1.03 (0.98 - 1.08) | 0.251 |
| Advanced | 1389 | 1.00 (0.94 - 1.06) | 0.914 | 0.229 |
| Fatal prostate cancer | 936 | 1.03 (0.97 - 1.10) | 0.325 |

This article is protected by copyright. All rights reserved.
|                          | Total prostate cancer | Grade | High | 95% CI            | P-value |
|--------------------------|-----------------------|-------|------|-------------------|---------|
|                          | 7036                  | Low   | 3757 | 1.00 (0.96 - 1.05) | 0.875   |
|                          |                       | High  | 726  | 0.97 (0.89 - 1.06) | 0.523   |
| Stage                    |                       |       |      |                   |         |
| Localized                | 2641                  |       |      | 1.02 (0.97 - 1.07) | 0.504   |
| Advanced                 | 1389                  |       |      | 1.00 (0.94 - 1.07) | 0.884   |
| Fatal prostate cancer    | 936                   |       |      | 1.06 (0.99 - 1.14) | 0.083   |

Cox regression analysis. All models are stratified by centre and age at recruitment and adjusted for age (underlying time variable), educational level (no degree, degree or unknown), smoking status (never, former, current or unknown), marital status (married, not married, unknown), diabetes (yes, no, unknown), physical activity (inactive, moderately inactive, moderately active, active, unknown), height (<170, 170–174, 175–179, ≥180 cm or unknown), body mass index (<22.5, 22.5–24.9, 25–29.9, ≥30 kg/m² or unknown), and total energy intake (fifths).

1 HR (95% CI) estimated per 1-SD increase in fatty acids intake.
2 Linear trends for HRs estimates over a continuous scale of the individual fatty acid.
3 P-value from test for heterogeneity for the associations of intake the individual fatty acids with risk of prostate cancer categorized according to prostate tumour grade (low-intermediate or high) and stage (localized or advanced).

Low-intermediate grade (Gleason score of <8, or grade coded as well, moderately, or poorly differentiated). High grade (Gleason score of ≥8, or grade coded as undifferentiated). Localized stage (TNM staging score of T0-T2 and N0/Nx and M0, or stage coded in the recruitment centre as localized). Advanced stage (T3-T4 and/or N1-N3 and/or M1, and/or stage coded in the recruitment centre as metastatic).

Abbreviation: PUFAs, polyunsaturated fatty acids.
Novelty and Impact
Are dietary fats associated with prostate cancer development and progression? In this large, prospective study, the authors found that, overall, the answer is no. However, a higher intake of butyric acid may be associated with an increased risk of advanced-stage prostate cancer, and higher intakes of eicosenoic and eicosapentaenoic acids may be positively associated with risk of lethal prostate cancer.